Gsa Capital Partners LLP Immunity Bio, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 107,985 shares of IBRX stock, worth $282,920. This represents 0.03% of its overall portfolio holdings.
Number of Shares
107,985
Previous 27,667
290.3%
Holding current value
$282,920
Previous $175,000
129.71%
% of portfolio
0.03%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$44.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$29.9 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$22.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$10.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.25MShares$5.89 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.05B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...